Clinical trial

Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer

NCT07825753

Drugs and interventions used in this trial

8 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Trastuzumab emtansine (T-DM1) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Trastuzumab deruxtecan (T-DXd) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Datopotamab deruxtecan (Dato-DXd) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Sacituzumab govitecan (SG) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Enfortumab vedotin (EV) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Becotatug vedotin (MRG003) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Izalontamab brengitecan (iza-bren / BL-B01D1) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Mirvetuximab soravtansine (MIRV) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-09-10

PhasePHASE2

Conditions

Advanced or Metastatic Pancreatic Adenocarcinomaunresolved

Advanced or Metastatic Breast Cancer (BC)unresolved

Interventions

Trastuzumab emtansine (T-DM1)DRUG

Trastuzumab deruxtecan (T-DXd)DRUG

Datopotamab deruxtecan (Dato-DXd)DRUG

Sacituzumab govitecan (SG)DRUG

Enfortumab vedotin (EV)DRUG

Becotatug vedotin (MRG003)DRUG

Izalontamab brengitecan (iza-bren / BL-B01D1)DRUG

Mirvetuximab soravtansine (MIRV)DRUG

Sponsors & collaborators

Fudan Universitylead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07825753 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.